Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06655246 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoints: 4 to 3 Study sites: 29 to 32 · Secondary endpoints revised (13) · Eligibility criteria shortened, about 4 words · 1 morev10 Show 4 more changesShow less
    • Study sites: 29 to 32
    • Secondary endpoints revised (13)
    • Eligibility criteria shortened, about 4 words
    • Study title shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 25 to 29v9
  3. Study sites: 23 to 25v8
  4. Study sites: 20 to 23v7
  5. Study sites: 10 to 20v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 2 to 10v5
  2. Start date changed from estimate of Apr 2025 to Mar 27, 2025v4
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2v3 Show 1 more changeShow less
    • Study sites: 0 to 2
  4. Start date: Jan 2025 to Apr 2025v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.
Trial Details
NCT Number NCT06655246
Lead Sponsor Kura Oncology, Inc.
Conditions Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant, Gastrointestinal Stromal Cell Tumors
Enrollment 157 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov